NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $13.76 -1.18 (-7.90%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$13.68 -0.08 (-0.58%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Greenwich LifeSciences Stock (NASDAQ:GLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$13.38▼$15.0450-Day Range$13.76▼$19.4852-Week Range$7.78▼$34.10Volume153,544 shsAverage Volume130,920 shsMarket Capitalization$202.00 millionP/E RatioN/ADividend YieldN/APrice Target$69.00Consensus RatingHold Company Overview Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product. The company is based in Stafford, Texas. Its founder and chief executive officer is Snehal Patel.AI Generated. May Contain Errors. Read More Greenwich LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreGLSI MarketRank™: 1.53096636412 of 5 starsGreenwich LifeSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 765th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGreenwich LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialGreenwich LifeSciences has a consensus price target of $69.00, representing about 401.5% upside from its current price of $13.76.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Greenwich LifeSciences are expected to grow in the coming year, from ($1.29) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -8.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -8.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 458.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.07% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 12.51, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 1.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.91 News SentimentGreenwich LifeSciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Greenwich LifeSciences this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders51.28% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLSI Stock News HeadlinesGreenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVNovember 13, 2026 | finance.yahoo.comGreenwich LifeSciences (GLSI) Expected to Post Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)3 Clinical-Stage Cancer Stocks With Pristine Balance SheetsSeptember 16, 2026 | finance.yahoo.comGreenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027August 10, 2026 | quiverquant.comQGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027August 10, 2026 | globenewswire.comGreenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22, 2026 | quiverquant.comQGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22, 2026 | globenewswire.comSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $21.01 at the start of the year. Since then, GLSI stock has decreased by 34.5% and is now trading at $13.76. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings results on Monday, November, 16th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $8 million in an initial public offering on Friday, September 25th 2020. The company issued 1,260,870 shares at $5.75-$6.75 per share. Aegis Capital served as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional investors include State Street Corp (1.09%), Goldman Sachs Group Inc. (0.39%) and Russell Investments Group Ltd. (0.01%). Insiders that own company stock include Snehal Patel and Jaye Thompson. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Greenwich LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Palantir Technologies (PLTR), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), FuelCell Energy (FCEL), Pfizer (PFE) and QuantumScape (QS). Company Calendar Today11/16/2026Last Earnings11/16/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GLSI's financial health is in the Red zone, according to TradeSmith. GLSI has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GLSI CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees13Year Founded2006Price Target and Rating Average Price Target for Greenwich LifeSciences$69.00 High Price Target$69.00 Low Price Target$69.00 Potential Upside/Downside+401.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-793.81% Return on Assets-295.32% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book458.67Miscellaneous Outstanding Shares14,680,000Free Float7,151,000Market Cap$202.00 million OptionableNot Optionable Beta1.57 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GLSI) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.